332,000 cases successfully underwent the cardiovascular intervention in mainland China in 2011, the drug-eluting stents used in which were mostly imported products. The China's home-grown innovative coronary artery stent with independent intellectual property right proclaimed by Professor Huo Yong, the chairman of the Cardiovascular Physician Division of the Chinese Medicine Doctor Association probably changed the condition.

The stent named “BuMA” was the first home-grown innovation by virtue of international cooperation instead of generic product, which was developed by SINO Medical Sciences Technology Inc. It takes the lead in resolving the hidden danger popular in the first generation drug-eluting stents strictly in accordance with the international standards, effectively inhibits thrombosis after coronary heart disease intervention and lays technical foundation for resolving the global problem of postoperative long-term medication.

The report indicated that the stent had similar effect on vascular endothelialization to the internationally accepted like stents. However, its current price is RMB 11, 000 and cheaper than foreign similar product by RMB 8,000. In the study the domestic drug-eluting stent was compared to the stent with the most market share in the world for the first time. It would not only affect the clinical treatment strategy but also was expected to provide more safety and higher cost-effective drug-eluting stent with shorter anti-platelet drug use period.

As far as is known, this drug-eluting stent developed by the SINO Medical Sciences Technology Inc has owned the III class medical device product registration certificate of the State Food and Drug Administration (SFDA). The product had application for international and domestic multi-invention and utility model patents, of which 7 items have been authorized by the SFDA and honored as “2011 National Key New products” by the Ministry of Science and Technology.